Advertisement

Supply Chain



Mylan banks on more than just prescription medications to make a profit. The drugmaker has achieved hundreds of millions of dollars in tax credits over the last six years by investing in refined coal, reports Reuters.

Neos Therapeutics on Monday earned Food and Drug Administration approval for its attention-deficit/hyperactivity disorder drug Cotempla.

Advertisement

Most Read

Advertisement
Advertisement